Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ZLDPF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 -67.67M
March 31, 2026 -1.253M
December 31, 2025 1.942M
September 30, 2025 -13.71M
June 30, 2025 -47.06M
March 31, 2025 -0.1116M
December 31, 2024 -35.78M
September 30, 2024 -40.09M
June 30, 2024 973.22M
March 31, 2024 265.17M
December 31, 2023 0.8072M
September 30, 2023 0.5885M
June 30, 2023 126.69M
March 31, 2023 4.347M
December 31, 2022 105.03M
September 30, 2022 -3.193M
June 30, 2022 -21.67M
March 31, 2022 -0.5218M
December 31, 2021 96.01M
September 30, 2021 -7.162M
June 30, 2021 2.032M
March 31, 2021 113.94M
December 31, 2020 -3.185M
September 30, 2020 1.660M
June 30, 2020 92.38M
Date Value
March 31, 2020 21.33M
December 31, 2019 2.737M
September 30, 2019 82.46M
June 30, 2019 2.000M
March 31, 2019 13.57M
December 31, 2018 0.3233M
September 30, 2018 -24.47M
June 30, 2018 0.0036M
March 31, 2018 -0.1159M
December 31, 2017 1.956M
September 30, 2017 76.81M
June 30, 2017 -0.3466M
March 31, 2017 -24.96M
December 31, 2016 20.42M
September 30, 2016 0.5363M
June 30, 2016 1.318M
March 31, 2016 0.5766M
December 31, 2015 3.494M
September 30, 2015 7.095M
June 30, 2015 2.681M
March 31, 2015 1.038M
December 31, 2014 45.68M
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Genmab A/S -74.60M
Ascendis Pharma A/S -53.34M
Bavarian Nordic A/S -36.42M
Evaxion AS --
ACADIA Pharmaceuticals, Inc. 10.49M